Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078723462> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W2078723462 endingPage "A269" @default.
- W2078723462 startingPage "A269" @default.
- W2078723462 abstract "Budget impact analysis of chronic hepatitis (HCV) pharmacotherapy with pegylated interferon alfa-2a (PegIFN alfa-2a) and pegylated interferon alfa-2b (PegIFN alfa-2b). The study used a Budget Impact Analysis method with the Rational Drug Use Indicator (RDUI), which allows to quantitatively describe the economic effectiveness of a particular drug taking into account its useful application potential. The modeling was based on the data collected in IDEAL clinical study. The model considered two groups of HCV genotype 1 patients, equal in number (1000 patients per group) and comparable in demographic, clinical, and virological characteristics: group 1 – patients receiving PegIFN alfa-2a, group 2 – PegIFN alfa-2b. Patients' age and weight, as well as the drug dose were taken into account. A sensitivity analysis was performed in modeling the number of patients treated with PegIFN alfa-2a and PegIFN alfa-2b. It is estimated that under the given model conditions the direct costs per patient in PegIFN alfa-2a treatment of hepatitis C for 48 weeks amounted to 419,199.36 rubles, and PegIFN alfa-2b – 422,637.12. The direct costs difference in the 1: 1 ratio of patients treated with PegIFN alfa-2a and PegIFN alfa-2b amounted to 1,718,880 rubles. As shown by the RDUI calculation, inefficient budget expenditure in the case of using PegIFN alfa-2b in 1,000 patients during the analyzed treatment period may reach 63,395,570 rubles. The results sensitivity analysis according to RDUI revealed a dependence of the budget losses on the share of patients receiving PegIFN alfa-2a and PegIFN alpha-2b. When comparing the budget impact by PegIFN alfa-2a and PegIFN alfa-2b HCV treatment strategies, the economic expediency of the strategy of using PegIFN alfa-2a in Russian patients was identified." @default.
- W2078723462 created "2016-06-24" @default.
- W2078723462 creator A5080622925 @default.
- W2078723462 date "2011-11-01" @default.
- W2078723462 modified "2023-09-28" @default.
- W2078723462 title "PIN19 Pharmacoeconomic Analysis of Pegylated Interferon Alfa Use in Chronic Hepatitis C" @default.
- W2078723462 doi "https://doi.org/10.1016/j.jval.2011.08.207" @default.
- W2078723462 hasPublicationYear "2011" @default.
- W2078723462 type Work @default.
- W2078723462 sameAs 2078723462 @default.
- W2078723462 citedByCount "0" @default.
- W2078723462 crossrefType "journal-article" @default.
- W2078723462 hasAuthorship W2078723462A5080622925 @default.
- W2078723462 hasBestOaLocation W20787234621 @default.
- W2078723462 hasConcept C126322002 @default.
- W2078723462 hasConcept C203014093 @default.
- W2078723462 hasConcept C2522874641 @default.
- W2078723462 hasConcept C2776178377 @default.
- W2078723462 hasConcept C2776455275 @default.
- W2078723462 hasConcept C2776461080 @default.
- W2078723462 hasConcept C2780040827 @default.
- W2078723462 hasConcept C2781228144 @default.
- W2078723462 hasConcept C2909179924 @default.
- W2078723462 hasConcept C3020491458 @default.
- W2078723462 hasConcept C500440147 @default.
- W2078723462 hasConcept C71924100 @default.
- W2078723462 hasConcept C90924648 @default.
- W2078723462 hasConceptScore W2078723462C126322002 @default.
- W2078723462 hasConceptScore W2078723462C203014093 @default.
- W2078723462 hasConceptScore W2078723462C2522874641 @default.
- W2078723462 hasConceptScore W2078723462C2776178377 @default.
- W2078723462 hasConceptScore W2078723462C2776455275 @default.
- W2078723462 hasConceptScore W2078723462C2776461080 @default.
- W2078723462 hasConceptScore W2078723462C2780040827 @default.
- W2078723462 hasConceptScore W2078723462C2781228144 @default.
- W2078723462 hasConceptScore W2078723462C2909179924 @default.
- W2078723462 hasConceptScore W2078723462C3020491458 @default.
- W2078723462 hasConceptScore W2078723462C500440147 @default.
- W2078723462 hasConceptScore W2078723462C71924100 @default.
- W2078723462 hasConceptScore W2078723462C90924648 @default.
- W2078723462 hasIssue "7" @default.
- W2078723462 hasLocation W20787234621 @default.
- W2078723462 hasOpenAccess W2078723462 @default.
- W2078723462 hasPrimaryLocation W20787234621 @default.
- W2078723462 hasRelatedWork W1922627677 @default.
- W2078723462 hasRelatedWork W2002416255 @default.
- W2078723462 hasRelatedWork W2030112683 @default.
- W2078723462 hasRelatedWork W2033665928 @default.
- W2078723462 hasRelatedWork W2035616141 @default.
- W2078723462 hasRelatedWork W2080043400 @default.
- W2078723462 hasRelatedWork W2408357797 @default.
- W2078723462 hasRelatedWork W2418726410 @default.
- W2078723462 hasRelatedWork W4231781806 @default.
- W2078723462 hasRelatedWork W2771873057 @default.
- W2078723462 hasVolume "14" @default.
- W2078723462 isParatext "false" @default.
- W2078723462 isRetracted "false" @default.
- W2078723462 magId "2078723462" @default.
- W2078723462 workType "article" @default.